Entrectinib

作用机制

Entrectinib is a selective tyrosine kinase inhibitor that acts by blocking the activity of specific abnormal proteins in cancer cells. It targets two proteins, TRKA and ROS1, which are frequently abnormal in various types of cancer and play a role in the growth and spread of these cancers. By inhibiting the activity of these proteins, entrectinib can slow down or stop the growth of cancer cells, and potentially shrink tumors.

TRKA is a receptor tyrosine kinase that is commonly altered in cancers such as lung cancer and neuroendocrine tumors. ROS1 is another receptor tyrosine kinase that is commonly altered in cancers such as non-small cell lung cancer, gastrointestinal stromal tumors, and cholangiocarcinomas.

Entrectinib is designed to target only the abnormal forms of these proteins, while having minimal impact on normal healthy cells. This targeted approach helps to minimize the side effects commonly associated with chemotherapy and other cancer treatments.

适应症

Entrectinib is a type of medication that is used in the treatment of solid tumors (such as non-small cell lung cancer (NSCLC), neuroendocrine tumors, and other types of cancer) that have a specific genetic alteration known as NTRK fusion.

Entrectinib works by blocking the activity of a protein called TRK, which is produced by the NTRK fusion gene and is involved in the development and growth of certain types of cancer. By blocking the activity of TRK, entrectinib helps to slow down the growth of cancer cells and can shrink the size of the tumor.

Dr. Reddy's的专长

Dr. Reddy's总部位于印度海得拉巴，是全球领先的活性药物成分（API）供应商之一。 Dr. Reddy's的API业务是美国、欧洲、巴西、拉丁美洲、日本、中国、韩国和新兴市场的制药公司的首选合作伙伴。

Dr. Reddy's博士的API业务在过去30多年来在开发和制造复杂API（如类固醇，多肽，复杂长链分子和高效API（HPAPI /肿瘤药物））方面所建立的深厚技术优势中茁壮成长。 我们在知识产权和法规事务方面的实力可以帮助我们始终如一地达到并超越监管标准，从而为这一专业知识提供补充。 Dr. Reddy's博士 Entrectinib API是研发，知识产权和监管方面广泛专业知识的结果。

帮助我们的客户率先进入市场的关键组成部分是响应式供应链。 我们通过确保所有设施都高效运行并达到最新的质量，安全和生产率标准来实现这一目标。 业务和工厂之间的强大互联可以快速响应动态的市场变化，从而避免短缺并满足需求的突然激增。